Carina Hillenbach - Concepedia

Author

Carina Hillenbach

Roche (Switzerland)

Also Known As

C Hillenbach, C. Hillenbach, Carina Hillenbach

Publications

809

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Lithuanian University of Health Sciences

About

Carina Hillenbach is an author at Roche (Switzerland) specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	643
2	Biostatistics	1	1	12
3	Emergency Medicine	1	1	150
4	Pharmacology	1	1	110
5	Pulmonary Disease	1	1	12

Carina Hillenbach

Publications

802

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas, The Lancet Oncology Second-line TreatmentOncologyCancer ManagementPoor PrognosisCancer Treatment	2012	371
Thromboembolic and Bleeding Complications Following St. Jude Medical Valve Replacement Detlef Hering, Cornelia Piper, R Bergemann, CHEST Journal ThrombosisVenous ThrombosisVascular SurgeryValve DiseaseCoagulopathy	2005	150
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study Christian Jackisch, S.-B. Kim, Semiglazov Vf, Annals of Oncology Breast OncologyOncologyPharmacologyImmune Checkpoint InhibitorBreast Cancer	2014	110
Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer Angelica Quartino, Carina Hillenbach, Jing Li, Cancer Chemotherapy and Pharmacology	2015	72
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma David Propper, John Bridgewater, Limas Kupčinskas, Annals of Oncology	2014	44
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer E.H. Tan, Rodryg Ramlau, A Płużańska, Annals of Oncology	2010	43
Lung Function Testing: The Dilemma of Predicted Values in Relation to the Individual Variability Xaver Baur, Paul O. Degens, R.N. Heitmann, Respiration AsthmaNormal RangesHealthy SubjectsAdvanced Lung DiseaseIndividual Variability	1996	12

Page 1